西安交通大学学报（医学版）2026，Vol.47Issue(1)：2-9,8.DOI:10.7652/jdyxb202601001
阿尔茨海默病Aβ免疫治疗的现状与展望
The current status and prospects of anti-Aβ immunotherapy for Alzheimer's disease
摘要
Abstract
The deposition of β-amyloid(Aβ)in the brain is a key pathogenesis and early change in Alzheimer's disease(AD).Clearing Aβ through active and passive immunity is an important strategy for preventing and treating AD.Since 2023,two anti-Aβ monoclonal antibodies,lecanemab and donanemab,have been launched successively,starting the era of Aβ immunotherapy.This article systematically reviews the history,current status,ongoing clinical research,and future development of Aβ immunotherapy.关键词
阿尔茨海默病(AD)/β-淀粉样蛋白(Aβ)/免疫治疗/抗Aβ单克隆抗体Key words
Alzheimer's disease(AD)/β-amyloid(Aβ)/immunotherapy/anti-Aβ monoclonal antibody分类
医药卫生引用本文复制引用
刘佩杰,崔思萌,高玲,王瑾,屈秋民..阿尔茨海默病Aβ免疫治疗的现状与展望[J].西安交通大学学报（医学版）,2026,47(1):2-9,8.基金项目
西安交通大学第一附属医院横向课题(No.HXIIT2024089)Supported by the Lateral Research Project of the First Affiliated Hospital of Xi'an Jiaotong University(No.HXIIT2024089) （No.HXIIT2024089）
